7 terminated. 7 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Terminated 7 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Hemangiosarcoma: new trials by email Literature Review of Hemangiosarcoma trials Research Report on Hemangiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
| Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study Quality-of-Life Assessment, Sintilimab - Locally Advanced Angiosarcoma, Metastatic Angiosarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-08-23 | 2026-07-21 |
| A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma Ontorpacept (TTI-621), Doxorubicin - Leiomyosarcoma | Phase 2 | Terminated | Pfizer | 76 | 2021-06-22 | 2024-12-11 |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma T-VEC - Angiosarcoma of Skin | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 5 | 2019-08-20 | 2022-11-01 |
| Evaluation of Votrient in Angiosarcoma Pazopanib + Paclitaxel - Angiosarcoma | Phase 2 | Terminated | Heidelberg University | 26 | 2014-07-01 | 2022-03-22 |
| Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma doxorubicin hydrochloride, trabectedin, laboratory biomarker analysis - Sarcoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 133 | 2011-05-01 | 2014-08-08 |
| Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma Bevacizumab, Paclitaxel - Angiosarcomas, Soft Tissue Sarcoma | Phase 2 | Terminated | Stanford University | 18 | 2010-02-01 | 2018-03-26 |
Sarcoma (3) · Leiomyosarcoma (2) · Carcinoma, Renal Cell (1) · Chondrosarcoma, Extraskeletal Myxoid (1) · Dermatofibrosarcoma (1) · Desmoplastic Small Round Cell Tumor (1) · Fibrosarcoma (1) · Hemangiopericytoma, Malignant (1) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma (1) · Malignant mesenchymal tumor (1) · Neurofibrosarcoma (1) · Sarcoma, Alveolar Soft Part (1) · Sarcoma, Synovial (1)
Neoplasms (7) · Neoplasms by Histologic Type (7) · Neoplasms, Connective and Soft Tissue (7) · Neoplasms, Vascular Tissue (7) · Sarcoma (4) · Neoplasms, Connective Tissue (2) · Neoplasms, Fibrous Tissue (2) · Neoplasms, Muscle Tissue (2) · Adenocarcinoma (1) · Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Fibrosarcoma (1) · Histiocytoma (1) · Kidney Diseases (1)
Doxorubicin (2) · Paclitaxel (2) · Albumin-Bound Paclitaxel (1) · Bevacizumab (1) · TTI-621 (1) · Trabectedin (1) · pazopanib (1) · sintilimab (1) · talimogene laherparepvec (1)
European Organisation for Research and Treatment of Cancer - EORTC (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Heidelberg University (1) · M.D. Anderson Cancer Center (1) · Pfizer (1) · Stanford University (1) · iOmx Therapeutics AG (1)
United States (5) · Austria (2) · Belgium (2) · France (2) · Germany (2) · Spain (2) · Denmark (1) · Hungary (1) · Netherlands (1) · Poland (1) · Slovakia (1) · Switzerland (1) · United Kingdom (1)
James E. Butrynski, MD (1) · John Mullinax, MD, (1) · Kristen N Ganjoo, MD (1) · Nguyen Binh Bui, MD (1) · Peter Hohenberger, MD (1) · Vinod Ravi (1)
2009 (1)